Form 4: Moderna President Stephen Hoge Discloses RSU Vesting and Tax-Related Stock Sale

Moderna President Stephen Hoge reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Stephen Hoge, President of Moderna, Inc., reported transactions involving Moderna common stock as part of a pre-planned Rule 10b5-1(c) transaction.
• On May 30, 2025, 652 shares of common stock were acquired through the conversion of restricted stock units (RSUs).
• Following this acquisition, 316 shares were disposed of at a price of $26.93 per share to satisfy tax withholding obligations related to the RSU vesting.
• After these transactions, Stephen Hoge directly beneficially owns 1,452,119 shares of Moderna common stock.
• Additionally, he indirectly owns 4,116 shares through Valhalla, LLC, and 151,933 shares through a trust for the benefit of his spouse and children.
• 1,955 Restricted Stock Units remain outstanding, with a vesting schedule of 25% on March 1, 2023, and the remainder vesting in twelve equal quarterly installments thereafter.

Sentiment

Score: 5

Explanation: The document is a routine SEC Form 4 filing disclosing executive compensation and tax-related share transactions, which are standard and expected events with no significant positive or negative implications for the company's operations or financial health.

Positives

• Vesting of Restricted Stock Units indicates a portion of executive compensation being realized, aligning executive interests with shareholder value.
• The acquisition of 652 shares through RSU conversion increases direct beneficial ownership before tax withholding, demonstrating continued equity stake.

Negatives

• A portion of shares (316 shares) was sold to cover tax liabilities, which is a common practice but results in a reduction of direct shareholding.

Future Outlook

The remaining 1,955 Restricted Stock Units will continue to vest in twelve equal quarterly installments following the initial 25% vesting on March 1, 2023, indicating ongoing equity compensation realization for the executive.

Industry Context

This filing is a routine disclosure of executive compensation and share transactions, common across publicly traded companies, particularly for executives receiving equity-based compensation like Restricted Stock Units. It reflects standard practices for managing vested equity and associated tax obligations within the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• The vesting of Restricted Stock Units and subsequent sale of shares for tax withholding purposes is a standard practice in executive compensation across various industries, including biotechnology and pharmaceuticals.
• Companies like Pfizer (PFE), Johnson & Johnson (J&J), and Merck (MRK) also utilize RSU programs for executive incentives, and similar Form 4 filings are routinely observed for their executives when RSUs vest and tax obligations are met.
• The specific price of $26.93 for tax withholding is a transactional detail and not directly comparable as an industry standard, but the mechanism of selling shares to cover taxes is universal.

Related Party Transactions

• Indirect ownership of 151,933 shares by a trust for the benefit of Dr. Hoge's spouse and children, with his spouse as a trustee. The reporting person disclaims Section 16 beneficial ownership except to the extent of pecuniary interest.

Stakeholder Impact

• Shareholders: This is a routine disclosure of executive compensation and does not directly impact shareholder value beyond the standard compensation practices.
• Employees: No direct impact on general employees.

Next Steps

• Remaining Restricted Stock Units will vest in twelve equal quarterly installments following the initial vesting on March 1, 2023.

Key Dates

Keywords

Moderna, MRNA, Stephen Hoge, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Executive Compensation, Rule 10b5-1(c)